Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee share options carry a 10-year term, with vesting tied to each recipient’s continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq: XENE) granted equity inducement awards to eight new non-officer employees, effective October 1, 2026, to support their hiring.
The awards comprise 17,850 share options and 10,500 restricted share units (RSUs). The options have an exercise price of $38.93 per common share, equal to the closing share price on the grant date. Both award types vest over four years, subject to continued service. The board’s Compensation Committee approved the grants under the company’s Amended and Restated 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.17,850 share options at a $38.93 exercise price create potential dilution as employee awards.
- Minor point. Forward-looking: it has not happened yet and may not happen.10,500 restricted share units create potential dilution, subject to four-year continued-service vesting.
Key Figures
- Employees receiving grants
- 8 employees
- New non-officer employees
- Share options
- 17,850 share options
- Aggregate inducement grants
- Restricted share units
- 10,500 RSUs
- Aggregate inducement grants
- Option exercise price
- $38.93 per common share
- Options granted October 1, 2026
- Option vesting period
- 4 years
- 25% after one year, then monthly vesting
- Option term
- 10 years
- Term for each option
- RSU vesting period
- 4 years
- 25% on each of the first four grant anniversaries
Historical Context
-
Prior grants under the same plan included four-year vesting and a 10-year option term.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Laura Perry/Emily Huang
Argot Partners
Xenon@argotpartners.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity inducement awards did Xenon Pharmaceuticals grant to new employees?
Xenon granted 17,850 share options and 10,500 restricted share units to eight new non-officer employees, effective October 1, 2026. The option exercise price is $38.93 per common share, equal to the closing share price on that date.
How do Xenon Pharmaceuticals’ October 1, 2026 inducement awards vest?
The options vest over four years: 25% on the first anniversary of each employee’s start date, followed by 1/36th of the remaining options monthly on the last day of each month. The RSUs vest 25% on each of the first four anniversaries of October 1, 2026. Both schedules require continued service.